Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma

Gynecologic Oncology

Volumn 65, Issue 1, 1997, Pages 149-157

  Rice, Laurel W ^a,b   Jazaeri, Amir A ^a   Shupnik, Margaret A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN;

ALTERNATIVE RNA SPLICING; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DNA SEQUENCE; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; EXON; FEMALE; HUMAN; HUMAN TISSUE; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SOUTHERN BLOTTING;

EID: 0031127159     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4623     Document Type: Article

References (44)

1. 1. Nayfield SJ, Karp JE, Ford LG, Dorr JA, Kramer BS: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83(20): 1450-1459, 1991
2. 2. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics (SEER). CA: Cancer J Clin 65:5-27, 1996
3. 3. Spratt JS, Donegan WL, Greenberg PA: Epidemiology and etiology, in Donegan WL, Spratt JS (eds): Cancer of the Breast. Philadelphia, Saunders, 1988, 3rd ed, pp 46-73
4. 4. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240:889-895, 1988
5. 5. Harris JR, Hellman S, Henderson IC: Breast Disease. Philadelphia, Lippincott, 1991
6. 6. Fisher B, Constantino J, Redmond C: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who has estrogen receptor positive tumors. N Engl J Med 320:479-484, 1989
7. 7. Turken S, Siris E, Seidin D, Flaster E, Hyman G, Lindsey R: Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:1086-1088, 1989
8. 8. Gottardis MM, Robertson SP, Satyaswaroop JP, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812-815, 1988
9. 9. Early Breast Cancer Trialist Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trial involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:11-15, 71-85, 1992
10. 10. Osborne CK, Coronodo E, Allred DC, Wiebe V, DeGregorio M: Acquired tamoxifen resistence: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477-1482, 1991
11. 11. Daly RJ, Darbre PD: Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res 50:5868-5875, 1990
12. 12. Mikicek RJ: Steroid receptor variants in their potential role in cancer. Semin Cancer Biol 5:369-379, 1994
13. 13. Green S, Walter P, Koumar V, Crust A, Bornert JM, Argos P, Chambon P: Human oestrogen receptor cDNA: Sequence, expression, and homology to v-erb-A. Nature 320:134-139, 1986
14. 14. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J: Sequence and expression of human estrogen receptor complimentary DNA. Science 231:1150-1154, 1986
15. 15. Kumar V, Green S, Stack G, Berry M, Jin J, Chambon P: Functional domains of the human estrogen receptor. Cell 51:941-951, 1982
16. 16. Kumar V, Chambon P: The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55:145-156, 1988
17. 17. Graham ML, II, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, Wei LL, Horwitz KB: T47Dco cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res 50:6208-6217, 1990
18. 18. Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Mally DW, McQuire WL: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51:105-109, 1991
19. 19. Murphy LC: Estrogen receptor variants in human breast cancer. Mol Cell Endocrinol 74:C83-C86, 1990
20. 20. Hirata S, Yamada-Mouri N, Nara M, Takazawa N, Ito H, Kato J: The presence of alternatively spliced-estrogen receptor mRNA variants in normal human uterine endometrium and endometrial cancer. Endocrin J 42(2):289-293, 1995
21. 21. Hu C, Hyder SM, Needleman DS, Baker W: Expression of estrogen receptor variants in normal and neoplastic human uterus. Mol Cell Endocrinol 118:173-179, 1996
22. 22. Sambrook J, Fritsch EF, Maniatis T (eds): Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989
23. 23. Friend KE, Chiou YK, Lopes MB, Laws ER, Hughes KM, Shupnik MA: Estrogen receptor expression in human pituitary: Correlation with immunohistochemistry in normal tissue and immunohistochemistry and morphology in microadenomas. J Clin Endocrinol and Metab 78(6): 1497-1504, 1994
24. R-1 compared to the parental MCF-7 cell line. Mol Cell Endo 109:197-207, 1995
25. 25. Fujimoto J, Hori M, Ichigo S, Nishigaki M, Itoh T, Tamaya T: Expression of aberrant estrogen receptor mRNA in endometrial cancers in comparison with normal endometria. Horm Res 42:116-119, 1994
26. 26. Dotzlaw H, Alkhalaf M, Murphy LC: Characterization of estrogen receptor variant mRNAs from human breast cancer. Mol Endocrinol 6:773-785, 1992
27. 27. Koehorst SGA, Cox JJ, Donker GH, Lopes da Silva S, Burbach JPH, Thijssen JHH, Blankenstein MA: Functional analysis of an alternatively spliced estrogen receptor lacking exon 4 isolated from MCF-7 breast cancer cells and meningioma tissue. Mol Cell Endocrin 101:237-245, 1994
28. 28. McGuire WL, Chamness GC, Fuqua SAW: Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571-1577, 1991
29. 29. Wang Y, Miksicek RJ: Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol 5:1707-1715, 1991
30. 30. Fuqua SAW, Chamness GC, McGuire WL: Estrogen receptor mutations in breast cancer. J Cell Biochem 51:135-139, 1993
31. 31. Leslie KK, Tasset DM, Horwitz KB: Functional analysis of a mutant estrogen receptor isolated from T47Dco breast cancer cells. Am J Obstet Gynecol 166:1053-1061, 1992
32. 32. Horwitz KB, McQuire WL: Estrogen control of progesterone receptor in human breast cancer: Correlation with nuclear processing of estrogen receptor. J Biol Chem 253:2223-2228, 1978
33. 33. Nomura Y, Miura S, Koyama H, Enomoto K, Kasumi F, Yamamoto H, Kimura M, Tominaga T, Iiona H, Morimoto T, Tashiro H: Relative effective steroid hormone receptors on the prognosis of patients with operable breast cancer. Cancer 69:153-164, 1991
34. 34. Kardinal CG: in Donegan WC, Spratt JS (eds): Endocrine Therapy of Breast Cancer, and Cancer of the Breast. Philadelphia, Saunders, 1988, 3rd ed, pp 501-540
35. 35. Muss HB: Endocrine therapy for advanced breast cancer: A review. Breast Cancer Res Treat 21:15-26, 1992
36. 36. Scott GK, Kushner P, Vigne JL, Benz CC: Truncated forms of DNA-binding estrogen receptors in human breast cancer. J Clin Invest 88:700-706, 1991
37. 37. Jozan S, Julia AM, Carretie A, Eche N, Maisongross CV, Fouet B, Marques B, David JF: Sixty-five and forty-seven kDa forms of estrogen receptor in human breast cancer: Relation with estrogen responsiveness. Breast Cancer Res Treat 19:103-109, 1991
38. 38. Graham ML, II, Smith JA, Jewett PB, Horwitz KB: Heterogeneity of progesterone receptor content and remodeling by Tamoxifen characterize subpopulations of cultured human breast cancer cells. Cancer Res 52:593-602, 1992
39. 39. Horwitz KB: Mechanisms of hormone resistence in breast cancer. Breast Cancer Res Treat 26:119-130, 1993
40. 40. Fuqua SA, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonneu DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52:483-486, 1992
41. 41. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP: Human estrogen receptor transactivational capacity is determined by both cellular and prometer context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:4-30, 1994
42. 42. Umayahara Y, Kawamori R, Watada H, Imano E, Iwana N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T: Estrogen regulation of the insulin-like growth factor gene transcription involves an AP-1 enhancer. J Biol Chem 269:16433-16449, 1994
43. 43. Philips A, Chalbos D, Rochefort H: Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268:14103-14108, 1993
44. 44. Webb P, Lopez GN, Uht RM, Kushner PJ: Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 8:443-456, 1995